Patent ID: 11866419
Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A compound of formula (IA) for use in the treatment of tuberculosis, wherein
R1 represents C1-6 alkyl or hydrogen;
L1 represents a linker group —C(Ra)(Rb)—;
X1 represents an aromatic linker group that is phenylene (which linker group may itself be optionally substituted by one or more substituents selected from fluoro, —OH, —OC1-6 alkyl and C1-6 alkyl, wherein the latter two alkyl moieties are themselves optionally substituted by one or more fluoro atoms);
Ra and Rb independently represent hydrogen or C1-6 alkyl (optionally substituted by one or more fluoro atoms);
Xa represents CH or N;
Xb represents CH, N, O (in which case L2 is not present) or C═O (in which case L2 is also not present);
q1 represents —CH2—, —CH2—CH2—, —O—CH2—, or “—”;
q2 represents —CH2—, or —CH2—CH2—;
q3 represents —CH2—, or —CH2—CH2—;
q4 represents —CH2—, or —CH2—CH2—;
when Xb represents O or C═O, then L2 is not present;
when Xb represents C(Ra) or N, then L2 may represent hydrogen, halo, —ORf, —C(O)—Rg, C1-6 alkyl (optionally substituted by one or more halo), or an aromatic group (optionally substituted by one or more substituents selected from halo, C1-6 alkyl (itself optionally substituted by one or more substituents selected from fluoro, —CF3 and/or —SF5), —OC1-6alkyl (itself optionally substituted by one or more fluoro atoms), —O-phenyl (itself optionally substituted by halo, C1-6alkyl, C1-6fluoroalkyl and/or —OC1-6alkyl) or —SF5); or, when Xb is N, L2 represents —S(O)2—C1-6alkyl optionally substituted by one or more fluoro atoms;
Rf represents hydrogen, C1-6 alkyl (optionally substituted by one or more fluoro) or an aromatic group (itself optionally substituted by one or more substituents selected from halo, C1-6alkyl and —OC1-6alkyl, where the latter two alkyl moieties may themselves be optionally substituted by one or more fluoro atoms);
Rg represents hydrogen or C1-6alkyl (optionally substituted by one or more substituents selected from fluoro, or —OC1-3 alkyl, which latter moiety is also optionally substituted by one or more fluoro atoms) or an aromatic group (optionally substituted by one or more substituents selected from halo, C1-6 alkyl or —OC1-6alkyl);
wherein the combined ring systems, i.e. Ring A and Ring B may be represented as follows:, either ring A and/or ring B may be optionally substituted by one or more substituents selected from: halo, C1-6 alkyl (optionally substituted by one or more halo) and/or —OC1-6alkyl (itself optionally substituted by one or more fluoro atoms),
or a pharmaceutically-acceptable salt thereof.